바로가기
본문 바로가기
메인메뉴 바로가기
CGRL
Cancer Genomics
Research Laboratory

Translational Research

Home > PUBLICATIONS > Translational Research

No. Journal File
47
 Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ., Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer., Invest New Drugs. , 2012 Aug;30(4):1404-12.
46
 Yoon YK, Im SA, Min A, Kim HP, Hur HS, Lee KH, Han SW, Song SH, Youn Oh D, Kim TY, Ho Kim W, Bang YJ., Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer., CANCER LETTERS 2012 Aug 28;321(2):128-36
45
 Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY., Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer., PLoS One. 2012;7(7):e39943.
44
 Yun J, Song SH, Park J, Kim HP, Yoon YK, Lee KH, Han SW, Oh DY, Im SA, Bang YJ, Kim TY., Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers., LABORATORY INVESTIGATION, 2012 Jul;92(7):1033-44.
43
 Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, Oh do Y, Im SA, Bang YJ, Yi EC, Kim TY., Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody., PLoS One. , 2012;7(3):e33322.
42
 Yoon YK, Kim HP, Song SH, Han SW, Oh DY, Im SA, Bang YJ, Kim TY., Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells., CANCER LETTERS, 2012 Mar;316(1):77-84.
41
 Nam HJ, Ching KA, Kan JL, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ., Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer., Mol Cancer Ther., 2012 Feb;11(2):439-51.
40
 Park JH, Park J, Choi JK, Lyu J, Bae MG, Lee YG, Bae JB, Park DY, Yang HK, Kim TY, Kim YJ., Identification of DNA methylation changes associated with human gastric cancer., BMC Med Genomics. , 2011 Dec 2;4:82.
39
 Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ, Kim TY., Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis., CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011 Jun;67(6):1323-31.
38
 Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ, Kim TY., Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab., Jpn J Clin Oncol. 2011 May;41(5):593-9.
37
 Kim JS, Kim MA, Oh DY, Lee SH, Kim DW, Im SA, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Kim TY. , Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study., JAPANESE JOURNAL OF CLINICAL ONCOLOGY 2011 Feb;41(2):245-52.
36
 Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY., High serum TGF-?? predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer., Breast Cancer Res Treat. , 2011 Jan;125(1):107-14.
35
 Kim SJ, Han SW, Oh DY, Yi NJ, Kim YJ, Im SA, Yoon JH, Kang GH, Suh KS, Bang YJ, Jang JJ, Kim TY., Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma., ANTICANCER RESEARCH, 2010 Dec;30(12):5245-50.
34
 Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, Song SH, Park J, Bang YJ, Kim TY., Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells., Molecules and cells, 2010 Aug;30(2):107-12.
33
 Kim H, Park J, Jung Y, Song SH, Han SW, Oh DY, Im SA, Bang YJ, Kim TY., DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells., INTERNATIONAL JOURNAL OF ONCOLOGY, 2010 Jun;36(6):1563-72.
32
 Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ, Kim TY., KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach., MOLECULAR CARCINOGENESIS, 2010 Apr;49(4):353-62.
31
 Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY., Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6., CANCER SCIENCE, 2010 Mar;101(3):793-9.
30
 Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY., Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells, MOLECULAR CANCER THERAPEUTICS, 2009 Sep;8(9):2526-36.
29
 Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY., Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2., PLOS ONE, 2009 Jun 16;4(6):e5933.
28
 Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK., Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival., BRITISH JOURNAL OF CANCER, 2009 Mar 10;100(5):732-8.
이전페이지 1 2 3 4 5 다음페이지